MedPath

Syringes Replacement for Insulin Application for Pens Device in a Population of Elderly Patients With Type 2 Diabetes: Multifactorial Intervention to Improve Glycemic Control

Phase 4
Conditions
Diabetes
Registration Number
NCT02517242
Lead Sponsor
Hospital de Clinicas de Porto Alegre
Brief Summary

This is a prospective, intervention, randomized, phase IV study. Patients will be included with 60 years or older, both sexes, with HbA1c \>8.5% using oral antidiabetics agents and insulin and then we will be randomized by use syringe or pens device to use insulin NPH and regular. All patients will receive a blood glucose monitor, lancet tapes, capillary blood glucose tests (3 tests/day). HbA1c will be measured at baseline, 3 and 6 months. Patients will see monthly.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
112
Inclusion Criteria
  • Sixty years or older
  • Diabetes type 2 with Glycated Hemoglobin higher than 8.5%
  • Using or necessity to use insulin
  • Using syringe to insulin
  • Using at least one oral antidiabetic
  • Accept to participate
Exclusion Criteria
  • Glomerular Filtration Rate lower than 30
  • Considering unfit for self administration of insulin

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Glycated Hemoglobinreduction compared to baseline values at six months

reduction compared to baseline values

Secondary Outcome Measures
NameTimeMethod
Blood Pressurereduction compared to baseline values at six months

Monthly measurements are made

adherencereduction compared to baseline values at six months

Monthly measurements are made

Number of pills, antidiabetics drugs and antihypertensives drugsreduction compared to baseline values at six months

Monthly measurements are made

Number of hypoglycemiasreduction compared to baseline values at six months

Monthly measurements are made

Presence of severe hypoglycemiasreduction of the number of patients with this outcome compared to baseline values at six months

Monthly measurements are made

Presence of nocturnal hypoglycemiasreduction of the number of patients with this outcome compared to baseline values at six months

Monthly measurements are made

Presence of asyntomatic hypoglycemiasreduction of the number of patients with this outcome compared to baseline values at six months

Monthly measurements are made

Trial Locations

Locations (1)

Rafael Vaz Machry

🇧🇷

Porto Alegre, Rio Grande do Sul, Brazil

Rafael Vaz Machry
🇧🇷Porto Alegre, Rio Grande do Sul, Brazil
Rafael Vaz Machry
Contact
(55)5196264337

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.